Skip to content
Home » EP 905 PILL – IDENTIFICATION, DOSAGE, SIDE EFFECTS

EP 905 PILL – IDENTIFICATION, DOSAGE, SIDE EFFECTS

EP 905 PILL

A white pill debossed with EP 905 on one side and 1 on the back is a generic formulation of Lorazepam 1 mg. Commonly recognized under the brand name Ativan, it belongs to the class of medications known as benzodiazepines.

Because lorazepam affects central nervous system activity, it is classified as a Schedule IV (CIV) controlled substance in the United States due to its potential for misuse, physical dependence, and addiction.

Pill Identification & Brand Details

EP 905 PILL
EP 905 PILL

Characteristic Specification

  • Brand Equivalent – Ativan
  • Active Ingredient – Lorazepam (1 mg)
  • Imprint Code – EP 905 (scored front) / 1 (back)
  • Drug Class – Benzodiazepine / Anxiolytic
  • Color – White
  • Shape – Round, flat-faced, beveled edge
  • Primary Manufacturer – Leading Pharma, LLC / Exelan Pharmaceuticals
  • Controlled Substance Class – Schedule IV (CIV)
  • Note: Pill imprints serve as unique identifiers required by the FDA. Always verify unidentified medications with a licensed pharmacist or healthcare provider before consumption.

Indications & Medical Uses

Lorazepam 1 mg is prescribed for several clinical applications:

  • Anxiety Disorders: Indicated for the management of generalized anxiety disorder (GAD) or short-term relief of severe anxiety symptoms.
  • Pre-anesthetic Medication: Used prior to surgery or surgical procedures to reduce anxiety, produce sedation, and induce amnesia for the procedure.
  • Insomnia: Prescribed for short-term management of insomnia caused by anxiety or temporary stress.
  • Seizure Control (Off-label / Parenteral Primary): While injectable lorazepam is a first-line treatment for status epilepticus, oral tablets are sometimes used as adjunctive maintenance therapy for certain seizure disorders.

Mechanism of Action

Lorazepam works as a central nervous system depressant by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain:

  • Selective Receptor Binding: Lorazepam binds to a specific allosteric site on the receptor complex in the central nervous system.
  • Enhancement of Inhibitory Signals: Binding increases the receptor’s affinity for GABA, opening chloride channels more frequently. The resulting influx of chloride ions hyperpolarizes the postsynaptic neuron, reducing neuronal excitability throughout the brain.
  • Therapeutic Effects: This widespread reduction in neural firing produces anxiolytic (anti-anxiety), sedative, muscle-relaxant, and anticonvulsant effects.

Dosage & Administration

Dosage must be strictly individualized based on age, symptom severity, and patient response.

Standard Adult Dosage for Anxiety:

  • Initial doses typically range from 2 mg to 3 mg daily, divided into 2 or 3 doses throughout the day (e.g., one 1 mg tablet taken two to three times daily).
  • The total daily dose usually ranges between 1 mg and 10 mg daily.

Dosage for Insomnia Due to Anxiety:

  • A single daily dose of 1 mg to 2 mg taken at bedtime.

Elderly or Debilitated Patients:

  • Initial dosage is usually reduced to 0.5 mg to 1 mg daily in divided doses to prevent excessive sedation or impaired motor coordination.
  • Administration: Can be taken with or without food. Tablets can be split along the score line if a 0.5 mg dose is prescribed.

Side Effects

Because benzodiazepines suppress central nervous system activity, side effects typically involve cognitive or motor slowing:

Common Side Effects

  • Sedation / Drowsiness
  • Dizziness or Lightheadedness
  • Unsteadiness or Ataxia (impaired coordination and balance)
  • Weakness or Muscle Fatigue
  • Confusion or Memory Impairment (anterograde amnesia)

Severe Side Effects (Seek Immediate Medical Attention)

  • Respiratory Depression: Abnormally slow or shallow breathing.
  • Paradoxical Reactions: Unexpected agitation, excitation, severe anxiety, or hallucinations.
  • Severe Allergic Reactions: Swelling of the face, lips, tongue, or throat; difficulty swallowing or breathing.
  • Depression / Suicidal Ideation: Worsening mood, severe lethargy, or thoughts of self-harm.

Precautions & Drug Interactions

  • Concomitant CNS Depressants: Combining lorazepam with alcohol, sleep medications, muscle relaxants, or other sedatives significantly increases the risk of severe sedation, coma, and respiratory failure.
  • Driving and Operating Machinery: Due to reduced reflexes and drowsiness, patients should avoid driving or operating dangerous equipment until they understand how the drug affects them.
  • Pre-existing Health Conditions:
  • Respiratory Compromise: Use with extreme caution in patients with COPD, sleep apnea, or other respiratory disorders.
  • Renal or Hepatic Impairment: Requires dose reduction and close monitoring due to altered drug clearance.
  • Glaucoma: Contraindicated in patients with acute narrow-angle glaucoma.

FDA Black Box Warnings & Addiction Risk

FDA BLACK BOX WARNINGS FOR BENZODIAZEPINES

  • Risks from Concomitant Use with Opioids: Taking benzodiazepines like lorazepam alongside opioid medications or illicit opioids can result in severe sedation, respiratory depression, coma, and death.
  • Abuse, Misuse, and Addiction: Lorazepam exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Assess each patient’s risk prior to prescribing.
  • Physical Dependence and Withdrawal: Continued use can lead to physical dependence. Abrupt cessation or rapid dose reduction can trigger life-threatening withdrawal symptoms, including grand mal seizures, severe tremors, psychosis, delirium, and severe rebound anxiety. Tapering must always be conducted under strict medical supervision.
  • Pregnancy & Breastfeeding: Lorazepam crosses the placenta and is excreted in human milk. Use during pregnancy is generally avoided due to the risk of congenital malformations and neonatal withdrawal/sedation syndromes. Breastfeeding while taking lorazepam is not recommended.

Leave a Reply